Fore Biotherapeutics

Fore Biotherapeutics (former Novellus) is a biotechnology company developing compounds for established oncogene drivers with a high incidence of uncharacterized mutations. Fore Biotherapeutics’ lead program, PLX-8394, is in clinical development for BRAF-mutated tumors without approved therapies.